DJIA 17,798.49 -14.90 -0.08%
NASDAQ 5,127.53 11.38 0.22%
S&P 500 2,090.11 1.24 0.06%
market minute promo

Amicus Therapeutics, Inc. (NASDAQ: FOLD)

11.53 0.20 (1.77%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

FOLD $11.53 1.77%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $11.30
Previous Close $11.33
Daily Range $11.22 - $11.78
52-Week Range $5.69 - $18.83
Market Cap $1.4B
P/E Ratio -10.30
Dividend (Yield) $0.00 (0.0%)
Volume 1,044,280
Average Daily Volume 2,825,942
Current FY EPS -$1.10




Drug Makers

Amicus Therapeutics, Inc. (FOLD) Description

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. Website:

News & Commentary

3 Biotech Stocks That Are Rocketing Higher

Acceleron Pharma, Cellectis SA, and Amicus Therapeutics' shares are surging higher during the past four weeks.

JPMorgan Likes These 5 Biotech Stocks

Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2015 Results - Earnings Call Transcript

Why Amicus Therapeutics Shares Are Soaring 10% Today

The company could offer up insight into its plans to file for FDA approval of Galafold when it reports earnings tomorrow.

Monday's ETF Movers: XBI, GDXJ

The Zacks Analyst Blog Highlights: Amgen, Regeneron, Acorda, Amicus and AbbVie

Biotech Stock Roundup: PBM Lists Both Amgen & Regeneron PCSK9 Inhibitors, FOLD Plunges on NDA Delay

Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Top 2 Trade Alert Ideas October 2: Geron Catalysts, Endocyte's Valuation, Drug Pricing

Amicus Therapeutics Plunges on Delay in NDA Submission

See More FOLD News...

FOLD's Top Competitors

FOLD $11.53 (1.77%)
Current stock: FOLD
AMGN $163.52 (-0.26%)
Current stock: AMGN
GILD $108.00 (0.20%)
Current stock: GILD
BIIB $293.21 (0.31%)
Current stock: BIIB